New mRNA mpox vaccine enters key trial in africa

NCT ID NCT07379580

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jan 31, 2026 · Last updated May 07, 2026 · Updated 14 times

Summary

This study tests a new mRNA vaccine (BNT166a) to see if it is safe and triggers a strong immune response against mpox (formerly monkeypox). About 310 healthy adults in African countries will receive either the vaccine or a placebo. The trial includes people who have never been exposed to mpox or smallpox, as well as those who have been vaccinated or infected before.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MPOX (MONKEYPOX) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Desmond Tutu Health Foundation Masiphumelele Clinic

    NOT_YET_RECRUITING

    Cape Town, 7975, South Africa

  • Institute National de Recherche Biomedicale

    NOT_YET_RECRUITING

    Kinshasa, 5345, Democratic Republic of the Congo

  • Perinatal HIV Research Unit

    RECRUITING

    Johannesburg, 1864, South Africa

  • TASK Applied Science

    NOT_YET_RECRUITING

    Cape Town, 7405, South Africa

  • TREAD Research Pty Ltd

    RECRUITING

    Cape Town, 7530, South Africa

  • University of Kinshasa UNIKIN

    NOT_YET_RECRUITING

    Kinshasa, 01306, Democratic Republic of the Congo

Conditions

Explore the condition pages connected to this study.